Companies waver in efforts to target transforming growth factor beta in cancer.
Garber
Ken
K
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000494:pharmacology*; D049109:Cell Proliferation / Q000187:drug effects; D002986:Clinical Trials as Topic / Q000639:trends; D003131:Combined Modality Therapy; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D051379:Mice; D008822:Mice, Transgenic; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D016376:Oligonucleotides, Antisense / Q000276:immunology; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D016212:Transforming Growth Factor beta / Q000009:adverse effects* / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D016376:Oligonucleotides, Antisense; D047428:Protein Kinase Inhibitors; D016212:Transforming Growth Factor beta